Effects of photodynamic therapy in combination with Adriamycin

Streckyte, Giedre; Didžiapetrienė, Janina; Grazeliene, G.; Prasmickiene, Grazina; Sukeliene, D; Kazlauskaitė, Nijolė; Characiejus, Dainius; Griciute, L; Rotomskis, Ričardas

doi:10.1016/s0304-3835(99)00241-4

Cited by 14 publications

(11 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dox has been shown to potentiate PDT responses in multiple studies 119, 120, 121, 122, 123, 124. Cowled et al first studied the interaction between PDT (with the HPD photosensitizer) and Dox both in vitro and in vivo 119.…”

Section: Combining Phototherapy With Chemotherapymentioning

confidence: 99%

Chemophototherapy: An Emerging Treatment Option for Solid Tumors

et al. 2016

View full text Add to dashboard Cite

Near infrared (NIR) light penetrates human tissues with limited depth, thereby providing a method to safely deliver non‐ionizing radiation to well‐defined target tissue volumes. Light‐based therapies including photodynamic therapy (PDT) and laser‐induced thermal therapy have been validated clinically for curative and palliative treatment of solid tumors. However, these monotherapies can suffer from incomplete tumor killing and have not displaced existing ablative modalities. The combination of phototherapy and chemotherapy (chemophototherapy, CPT), when carefully planned, has been shown to be an effective tumor treatment option preclinically and clinically. Chemotherapy can enhance the efficacy of PDT by targeting surviving cancer cells or by inhibiting regrowth of damaged tumor blood vessels. Alternatively, PDT‐mediated vascular permeabilization has been shown to enhance the deposition of nanoparticulate drugs into tumors for enhanced accumulation and efficacy. Integrated nanoparticles have been reported that combine photosensitizers and drugs into a single agent. More recently, light‐activated nanoparticles have been developed that release their payload in response to light irradiation to achieve improved drug bioavailability with superior efficacy. CPT can potently eradicate tumors with precise spatial control, and further clinical testing is warranted.

show abstract

Section: Combining Phototherapy With Chemotherapymentioning

confidence: 99%

Chemophototherapy: An Emerging Treatment Option for Solid Tumors

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Adriamycin is an anthracycline antibiotic whose cytotoxic activities include intercalation into DNA [13], interactions with membranes [14] and bioreductive activation leading to the formation of drug and oxygen free radicals and alkylating species [15]. Several reports have indicated synergism of photodynamic therapy with Adriamycin in vitro and in animal tumor models [16]. However, Adriamycin used clinically has shown some adverse effects, and these side effects with the use of Adriamycin compelled researchers to search for new second-generation antitumor agents and/ or drugs combined with other antitumor antibiotics or immunomodulators [17,18].…”

Section: Introductionmentioning

confidence: 99%

Topoisomerase I Inactivation by Reticulol and Its in vivo Cytotoxicity against B16F10 Melanoma

et al. 2003

View full text Add to dashboard Cite

To investigate the enzyme-inhibitory efficacy and the cytotoxicity of reticulol produced from a strain of Streptoverticillium, we conducted a DNA topoisomerase (Topo) cleavage assay and an in vivo assay using B16F10 melanoma. From the inhibition assay of reticulol for Topo I, which is involved in melanoma metastasis, it was seen that Topo I treated with 45 µM reticulol did not replicate or transcribe DNA by forming supercoiled DNA. In the annexin V/propidium iodide staining assay to investigate the death pattern of B16F10 cells treated with 200 µM reticulol, proliferation of B16F10 cells was inhibited due to necrosis. Furthermore, from the in vivo assay, reticulol combined with Adriamycin (a mixture with retinolol 5 mg/kg and Adriamycin 1 mg/kg) further retarded the tumor growth compared to that in mice treated with Adriamycin alone (1 mg/kg). The survival rate of tumor-bearing mice treated with the mixture was closely associated with its cytotoxicity. Taken together, these results suggested that reticulol inactivates Topo I, which is involved in tumor metastasis, and exhibits excellent cytotoxic efficacy against B16F10 melanoma, when combined with Adriamycin, in a mouse model.

show abstract

“…PDT in combination with surgery [15] , radiotherapy [16] or chemotherapy [17] , has become a subject of research. New photosensitizers with improved spectroscopic, photochemical and tissue-localizing properties and improved laser instrumentation have stimulated attempts to establish clinical protocols for incorporation of PDT into multi-treatment modalities [18][19][20][21][22][23][24] . Most studies on PDT to date have been on lesions of the skin or in the wall of hollow organs, but recent interest is more in its potential for treating lesions of solid organs such as the pancreas [10,11,20] .…”

Section: Introductionmentioning

confidence: 99%

Synergetic anticancer effect of combined gemcitabine and photodynamic therapy on pancreatic cancer in vivo

Xie¹,

Jia²,

Liu³

et al. 2009

WJG

View full text Add to dashboard Cite

AIM:To investigate the anti-tumor effects of combined cytotoxic drug (gemcitabine) and photodynamic therapy (PDT) on human pancreatic cancer xenograft in nude mice. METHODS:Human pancreatic cancer cell line SW1990 was used in the investigation of the in vivo effect of combined gemcitabine and PDT on human pancreatic cancer xenograft in mice. Sixty mice were randomly allocated into a control group (without treatment), photosensitizer treatment group (2 mg/kg photosan, without illumination), chemotherapy group (50 mg/kg gemcitabine i.p.), PDT group (2 mg/kg photosan + laser irradiation) and combined treatment group (photosan + chemotherapy), with 12 mice in each group. Tumor size was measured twice every week. Anti-tumor activity in different groups was evaluated by tumor growth inhibition (TGI). RESULTS:No significant anti-tumor effect was observed either in photosensitizer treatment group or in chemotherapy group. PDT led to necrosis in cancer lesions and significantly reduced tumor volume compared with photosensitizer on day 6 and at the following time points after initialization of therapy (0.24 ± 0.15-0.49 ± 0.08 vs 0.43 ± 0.18-1.25 ± 0.09, P < 0.05). PDT significantly reduced tumor volume in combined treatment group compared with photosensitizer treatment group (0.12 ± 0.07-0.28 ± 0.12 vs 0.39 ± 0.15-1.20 ± 0.11, P < 0.05), small dose chemotherapy group (0.12 ± 0.07-0.28 ± 0.12 vs 0.32 ± 0.14-1.16 ± 0.08, P < 0.05) and control group (0.12 ± 0.07-0.28 ± 0.12 vs 0.43 ± 0.18-1.25 ± 0.09, P < 0.05). TGI was higher in the combined treatment group (82.42%) than in the PDT group (58.18%). CONCLUSION:PDT has a significant anti-tumor effect, which is maintained for a short time and can be significantly enhanced by small doses of gemcitabine.

show abstract

Effects of photodynamic therapy in combination with Adriamycin

Cited by 14 publications

References 25 publications

Chemophototherapy: An Emerging Treatment Option for Solid Tumors

Chemophototherapy: An Emerging Treatment Option for Solid Tumors

Topoisomerase I Inactivation by Reticulol and Its in vivo Cytotoxicity against B16F10 Melanoma

Synergetic anticancer effect of combined gemcitabine and photodynamic therapy on pancreatic cancer in vivo

Contact Info

Product

Resources

About